Dr. Eugene Suh
Claim this profileLoyola University Medical Center
About Eugene Suh
Education:
- Earned an MD from Loyola University Chicago Stritch School of Medicine in 2015.
Experience:
- Completed a Residency in Internal Medicine at Loyola University Medical Center in 2018.
- Finished a Fellowship in Cardiovascular Disease at Loyola University Medical Center in 2021.
Area of expertise
Brain Tumor
Eugene Suh has run 9 trials for Brain Tumor. Some of their research focus areas include:
Rhabdomyosarcoma
Eugene Suh has run 8 trials for Rhabdomyosarcoma. Some of their research focus areas include:
Affiliated Hospitals
Loyola University Medical Center
Clinical Trials Eugene Suh is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Lower Radiotherapy Dose
for Brain Tumors
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
Recruiting
1 award
Phase 2
10 criteria
More about Eugene Suh
Clinical Trial Related
8 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Eugene Suh has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Carboplatin
Breakdown of trials Eugene Suh has run
Brain Tumor
Rhabdomyosarcoma
Cancer
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eugene Suh specialize in?
Eugene Suh focuses on Brain Tumor and Rhabdomyosarcoma. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are Stage I.
Is Eugene Suh currently recruiting for clinical trials?
Yes, Eugene Suh is currently recruiting for 13 clinical trials in Maywood Illinois. If you're interested in participating, you should apply.
Are there any treatments that Eugene Suh has studied deeply?
Yes, Eugene Suh has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Eugene Suh?
Apply for one of the trials that Eugene Suh is conducting.
What is the office address of Eugene Suh?
The office of Eugene Suh is located at: Loyola University Medical Center, Maywood, Illinois 60153 United States. This is the address for their practice at the Loyola University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.